New cancer drug shows promise for Hard-to-Treat tumors and brain spread
NCT ID NCT07359066
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called SPR1020 in adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to target cancer cells with specific genetic changes (BRCA or HRR mutations) and may also reach brain tumors. The goal is to find a safe dose and see if it can shrink tumors while causing fewer side effects than older similar drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED EPITHELIAL OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
NOT_YET_RECRUITINGBeijing, Beijing Municipality, China
-
The Affiliated Tumor Hospital of Harbin Medical University
RECRUITINGHarbin, Heilongjiang, 150081, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?